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P E R S P E C T I V E S
Exome Sequencing: current and future perspectives 
Amanda Warr*, Christelle Robert*, David Hume*, Alan Archibald*, Nader Deeb§ and Mick Watson* 
* The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush, Edinburgh EH25 9RG, UK
§ Genus plc., Hendersonville, TN 37075, USA
ABSTRACT The falling cost of DNA sequencing has made the technology affordable to many research groups, 
enabling researchers to link genomic variants to observed phenotypes in a range of species. This review focusses 
on whole exome sequencing and its applications in humans and other species. The exome has traditionally been 
defined to consist of only the protein coding portion of the genome; a region where mutations are likely to affect 
protein structure and function. There are several commercial kits available for exome sequencing in a number 
of species and, owing to the highly conserved nature of exons, many of these can be applied to other closely 
related species. The data set produced from exome sequencing is many times smaller than that of whole 
genome sequencing, making it more easily manageable and the analysis less complex. Exome sequencing for 
disease gene discovery in humans is well established and has been used successfully to identify mutations that 
are causative of complex and rare diseases. Exome sequencing has also been used in a number of domesticated 
and companion species. The successful application of exome sequencing to crops has yielded results that may 
be used in selective breeding to improve production in these species, and there is potential for exome sequenc-
ing to provide similar advances in livestock species that have not yet been realised.
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INTRODUCTION
The completion of a reference genome sequence for humans took more 
than 200 scientists over a decade in a project that cost almost $3 billion 
to complete (International Human Genome Sequencing Consortium 
2004). Over the past decade the price of genome sequencing has plum-
meted, much of the work has become automated and methods have 
improved. These advances mean complete genomes can be sequenced 
quickly and affordably. Human genome sequencing is a special case and 
enjoys much lower cost-per-gigabase than other species due to Illumi-
na’s HiSeq X platform (Watson 2014). Sequencing can allow for the 
identification of genetic variants that affect heritable phenotypes in-
cluding important disease-causing mutations and natural variation that 
can be exploited to improve crops and livestock. Despite the significant 
improvement in sequencing technology, sequencing whole genomes to 
a depth sufficient to find variants that affect phenotypic expression is 
expensive when compared with targeted sequencing. This review will 
focus on exome sequencing: a method which targets only a subset of the 
genome, often the protein coding portion, significantly reducing the 
sequencing space and subsequently the cost. Details of the method, 
available platforms, uses in humans and other species and its benefits 
over whole genome sequencing (WGS) will be discussed.
WHAT IS EXOME SEQUENCING?
The exome has been traditionally defined as the sequence encompassing 
all exons of protein coding genes in the genome and covers between 1% 
and 2% of the genome, depending on species. It may also be extended 
to target functional non-protein coding elements (e.g. miRNA, lin-
cRNA etc.) as well as specific candidate loci. There are two main catego-
ries of exome capture technology: solution-based and array-based. 
In solution-based whole exome sequencing (WES), DNA samples 
are fragmented and biotinylated oligonucleotide probes (baits) are used 
to selectively hybridise to target regions in the genome. Magnetic strep-
tavidin beads are used to bind to the biotinylated probes, the non- 
targeted portion of the genome is washed away and the polymerase 
chain reaction (PCR) is used to amplify the sample, enriching the sam-
ple for DNA from the target region. The sample is then sequenced 
before proceeding to bioinformatic analysis. Array-based methods are 
similar except that the probes are bound to a high-density microarray. 
The array-based method was the first to be used in exome capture 
(Albert et al. 2007), but it has largely been supplanted by solution-based 
methods, which require less input DNA and are consequently poten-
tially more efficient; however, studies by Asan et al. (2011) and Bodi et 
al. (2013) found that NimbleGen’s Sequence Capture Array performed 
better than the solution-based alternatives in low GC content regions; 
had high sensitivity and read mapping rates; and single nucleotide poly-
morphism (SNP) detection from these reads was more specific to the 
target region. This suggests that a niche may remain for the older tech-
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nology. Array-based capture has been used successfully and accurately 
to identify rare and common variants and identify candidate genes for 
monogenic diseases in small cohorts (Ng et al. 2009); however, the 
array-based methods are less scalable owing to the limitation of the 
number of probes that can be accommodated on the array and addi-
tional equipment and time required to process the microarrays.
EXOME CAPTURE PLATFORMS
There are several differences between the available platforms, which are 
constantly being updated and improved. The major providers of exome 
capture platforms are NimbleGen, Agilent and Illumina and each have 
different designs and strengths (Summarised in Table 1). The discus-
sion of the characteristics of each platform will focus on the solution-
based human kits; the performance of kits for other species has not been 
subjected to the same level of comparison.
NimbleGen’s SeqCap EZ Exome Library has the highest bait density 
of any of the platforms, utilising short (55-105 bp), overlapping baits to 
cover the target region (Clark et al. 2011). This approach has been found 
to be an efficient method for enrichment with the least amount of 
sequencing needed to cover the target region and sensitively detect vari-
ants (Clark et al. 2011) and also has a high level of specificity showing 
fewer off-target reads than other platforms (Clark et al. 2011; Sulonen et 
al. 2011). Importantly, this bait design has been found to show greater 
genotype sensitivity and more uniformity of coverage in difficult to se-
quence regions, such as areas of high GC content, than the other plat-
forms (Asan et al. 2011; Sulonen et al. 2011; Bodi et al. 2013). 
Agilent’s SureSelect Human All Exon Kit is the only platform to use 
RNA probes, with the other platforms opting for DNA probes. The 
baits used are longer than those used in NimbleGen’s platform (114-
126 bp) and the corresponding target sequences are adjacent to one 
another rather than overlapping (Clark et al. 2011). This design has 
been found to be good at identifying insertions and deletions (indels) as 
longer baits can tolerate larger mismatches (Clark et al. 2011; Bodi et al. 
2013; Chilamakuri et al. 2014); it has been suggested that this may also 
reduce reference allele bias at heterozygous sites compared to other bait 
designs, however in practice the allele bias has been similar to other 
platforms (Asan et al. 2011; Hedges et al. 2011). The platform has been 
found to produce fewer duplicate reads than NimbleGen, but also fewer 
high quality reads (Sulonen et al. 2011). Bodi et al. (2013) found that 
Agilent had a higher alignment rate and fewer PCR duplicates than 
NimbleGen, but also had less uniform coverage.
Illumina’s TruSeq Exome Enrichment Kit uses 95 bp probes that 
leave small gaps in the target region, with paired end reads extending 
outside the bait sequence during sequencing to fill the gap. This design 
has been found to have a high percentage of off-target enrichment 
(Clark et al. 2011) which reduces its target efficiency compared to the 
other platforms. This kit detects more SNVs in the untranslated regions 
(UTRs) than the other platforms (Clark et al. 2011), though compari-
sons of performance with NimbleGen and Agilent’s “+UTR” kits have 
yet to be performed. Following filtering for duplicates, multiple map-
pers, improper pairs and off-target reads, Chilamakuri et al. (2014) 
found that this platform retained fewer reads (54.8%) than NimbleGen 
(66%) or Agilent (71.7%). At high read counts (>50M), this platform 
outperformed Agilent’s SureSelect in downstream identification of in-
dels (Clark et al. 2011). 
Illumina’s Nextera Rapid Capture Exome and Expanded Exome kits 
are similar to the TruSeq kit in their probe design. They differ from the 
other kits in that they use transposomes to fragment the genomic DNA, 
whereas the other platforms use ultrasonication. These kits have not 
been extensively compared to the other platforms with only Chilamakuri 
et al. (2014) having included Nextera in a comparison study. At the time 
of the study there was only one Nextera kit which was the Expanded 
Exome version: the kit with the larger target region of the two. The 
Expanded Exome kit shares a target region with the TruSeq kit which 
includes UTRs and miRNAs. Chilamakuri et al. (2014) found that the 
Nextera kit had increased coverage of high GC content areas due to 
altered bias in the transposome technology used during fragmentation, 
decreasing its overall uniformity; however recent changes to the proto-
col in the new versions may have improved this. They also found that 
out of all platforms tested, the Nextera platform retained the fewest 
■ Table 1 Summary of the differences between the solution-based exome sequencing platforms
 NimbleGen’s SeqCap  Agilent’s Sure Select  Illumina’s TruSeq  Illumina’s Nextera Rapid  
 EZ Exome Library Human All Exon Kit Exome Enrichment Kit Capture Exome Kit
Probe Sizea 55–105 bp 114–126 bp 95 bp 95 bp
Probe Type DNA RNA DNA DNA
Coverage Strategy High-density,  Adjacent probes Gaps between probes Gaps between probes 
 overlapping probes
Fragmentation Method Ultrasonication Ultrasonication Ultrasonication Transposomes
Target region size (Human)b 64Mb 50Mb 62Mb 62Mb
Reads remaining following 66% 71.7% 54.8% 40.1% 
filteringc
Major strengths (i) High sensitivity  (i) Better coverage of indels (i) Good coverage of (i) Good coverage of 
 and specificity (ii) High alignment rate UTRs and miRNAs UTRs and miRNAs 
 (ii) Most uniform coverage  (iii) Fewer duplicate reads 
 in difficult regions than other platforms 
Major weaknesses (i) More duplicate reads (i) Fewer high quality reads  (i) High off-target (i) High off-target 
 than Agilent than NimbleGen enrichment enrichment 
 (ii) Lower alignment rate    (ii) Coverage bias for 
 than Agilent   high GC content areas   
    reducing uniformity
Non-human supported ✔ ✔	 ✘	 ✘
a As described in Clark et al. (2011)-  NimbleGen SeqCap EZ v2.0, Agilent SureSelect Human All Exon 50Mb, Illumina TruSeq Exome Enrichment
b For NimbleGen SeqCap EZ v3.0, Agilent SureSelect V5, and Illumina TruSeq and Illumina Nextera original versions
c Filtering for duplicates, multiple mappers, improper pairs and off-target reads, data from Chilamakuri et al. (2014)
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reads after filtering for duplicates, multiple mappers, improper pairs 
and off-target reads, at 40.1%. 
Chilamakuri et al. (2014) compared the target regions of the human 
kits from three providers (NimbleGen SeqCap EZ v3.0 – 64.1Mb; 
Agilent SureSelect V4 – 51.1Mb; and Illumina TruSeq and Illumina 
Nextera original version and protocol – 62.08 Mb). Despite the fact that 
all of the platforms are targeting the human exome, there is surprisingly 
little overlap between the three designs with just 26.2 Mb covered by all 
three target regions. NimbleGen’s and Agilent’s coverage are more 
similar to one another than either are to Illumina’s; this is likely due to 
the large amount of UTRs covered in Illumina’s target region. Illumina 
has 22.5Mb of targets unique to their platforms and 21.8Mb of these 
are UTRs. NimbleGen and Agilent have 16.1Mb and 7Mb of unique 
targets, respectively. It would be interesting to see how NimbleGen and 
Agilent’s “+UTR” kits compare to Illumina in SNV calling, particularly 
in UTRs.
Currently, in addition to human kits, NimbleGen offer capture kits 
for maize, barley, wheat, soy, mouse and pig exomes and Agilent offer 
capture kits for mouse, cattle and zebrafish exomes. Both providers also 
offer the opportunity to design custom kits for other species. The kits 
for non-human species use similar bait designs and protocols to the 
providers’ human kits. Both manufacturers offer a flexible design pro-
cess allowing for modifications to improve coverage for specific regions 
and purposes. 
USES IN HUMANS
The first successful use of WES to diagnose and inform subsequent 
treatment in a human patient was in the identification of the causal 
variant of a rare form of Inflammatory Bowel Disease (IBD) in an infant 
(Worthey et al. 2011). In this case conventional diagnostics had failed to 
find an explanation for the patient’s severe symptoms and doctors 
needed to understand the underlying cause of the symptoms before 
they could decide how to treat the child. A multidisciplinary team com-
bined clinical phenotyping, exome sequencing, bioinformatics and 
functional studies, eventually finding the causative mutation which 
influenced the future treatment of the child. The analysis of the exome 
data was hampered by the relative lack of software designed for this 
purpose at the time and researchers had to manually inspect over 2000 
variants. Through filtering and manual inspection the candidate pool 
was reduced to 70 genes exhibiting hemi- or homozygous variants. Of 
these only eight variants were novel and predicted to be damaging to 
protein function. Analysis of evolutionary conservation identified two 
variants that were located in highly conserved sequences and one of 
these had a high null genotype frequency. This left a single hemizygous, 
non-synonymous variant in the X-linked inhibitor of apoptosis (XIAP) 
gene. The child was diagnosed with X-linked lymphoproliferative dis-
ease 2, exhibiting a novel IBD-like manifestation caused by loss of toler-
ance to commensal organisms in the digestive system. This diagnosis 
allowed for effective treatment through allogeneic hematopoietic pro-
genitor cell transplant. The unusual manifestation of the condition 
meant that the patient was unlikely to have been diagnosed without the 
exome sequence data.
Following the success of this initial diagnosis, exome sequencing has 
been used extensively to diagnose novel diseases and find novel caus-
ative mutations for known disease phenotypes. Exome sequencing is 
useful in human medicine for diagnosis of particularly difficult to diag-
nose patients, diagnosis of young patients who may not yet exhibit a full 
spectrum of symptoms (Iglesias et al. 2014), prenatal diagnosis (Iglesias 
et al. 2014; Xu et al. 2014) and early diagnosis of debilitating disease 
(Bras and Singleton 2011; Sassi et al. 2014). In addition to reaching a 
diagnosis, finding the causative mutation can allow for alteration of 
treatment, prevention of further invasive testing, accurate prognoses, 
and confirmed diagnoses which are essential for eligibility for benefits 
and access to clinical trials (Grossmann et al. 2011; Rabbani et al. 2012; 
Taneri et al. 2012; Iglesias et al. 2014) and in the future may allow for 
more targeted treatment.
Exome sequencing in human medicine benefits from the availabil-
ity of large databases of known SNPs, known pathogenic variants and 
control genomes; during analysis variants found in these databases 
can generally be excluded when looking for novel variants, signifi-
cantly reducing the variant pool. The Exome Aggregation Consor-
tium (ExAC) has created a user-friendly database containing the 
exome sequences of over 60,000 unrelated individuals, which is 
freely available (Exome Aggregation Consortium (ExAC) 2014). The 
exomes have been analysed using a uniform bioinformatic pipeline 
and are from individuals with adult-onset diseases. This provides re-
searchers with a large set of reference exomes which should be free 
from homozygous variants that cause childhood-onset Mendelian 
diseases. The database provides a wealth of information such as depth 
of coverage, genotype quality, allele frequency and variant conse-
quences. The filtering capabilities and large number of exomes will 
simplify the process of prioritising variants when using exome 
sequencing as a diagnostic tool, particularly in children. 
Where many unrelated, affected individuals are available, an ‘over-
lap’ strategy can be used to simplify analysis and search for common 
variants likely to affect gene function (Johansson et al. 2012). If there is 
a known inheritance pattern this can be used to search for specific gen-
otype zygosity. Sequencing of multiple affected related individuals can 
also increase the power of the analysis (Johnson et al. 2010; Shi et al. 
2011). In rare diseases, case-parent trios can be used to exclude non-
pathogenic variants found in the parents (Smith et al. 2014). However, 
single patient sequencing may be sufficient to identify the causative mu-
tation (Wang et al. 2011; Worthey et al. 2011; Xu et al. 2014). Analysis 
examining how conserved an amino acid sequence is through evolution 
and between genes in a family can help to increase the confidence of a 
mutation having a deleterious effect (Wang et al. 2011; Johansson et al. 
2012; Sassi et al. 2014; Smith et al. 2014; Xu et al. 2014). 
Examples of diseases for which exome sequencing has been used to 
detect a causative variant include Leber Congenital Amaurosis (Wang 
et al. 2011), Alzheimer’s Disease (Sassi et al. 2014), Maturity-Onset 
Diabetes of the Young (Johansson et al. 2012), High Myopia (Shi et al. 
2011), Autosomal Recessive Polycystic Kidney Disease (Xu et al. 2014), 
Amyotrophic Lateral Sclerosis (Johnson et al. 2010), immunodeficiency 
leading to infection with human herpes virus 8 causing Kaposi Sarcoma 
(Byun et al. 2010), Acromelic Frontonasal Dystois (Smith et al. 2014) 
and a number of cancer predisposition mutations (e.g. Yan et al. 2011; 
Greif et al. 2012; Snape et al. 2012; Kiiski et al. 2014; Cai et al. 2015).
The Deciphering Developmental Disorders (DDD) project aims to 
develop a scalable exome sequencing workflow to facilitate the transla-
tion of the method from the research environment to a clinical environ-
ment. So far over 1,000 children with undiagnosed developmental 
disorders and their parents have been sequenced with plans to increase 
this number to 12,000 patients. With diagnostic yields up to 31% in the 
children sequenced so far, this project demonstrates the future potential 
of the method in a clinical setting (Gecz and Corbett 2015; Wright et al. 
2015; The Deciphering Developmental Disorders 2015).
USES IN OTHER SPECIES
Variants discovery for agricultural improvement
Not all protein-altering variants cause disease (MacArthur and Tyler-
Smith 2010). To understand the potential of exome sequencing in areas 
other than disease variant discovery, which is the main focus in human 
research, we can look to studies using the technique to sequence agri-
cultural species. 
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Plant genomes can be extremely complex, repetitive and are often 
polyploid; as a result some of the most economically important crops 
are not well suited for genome re-sequencing studied. For example, 
Bread Wheat (Triticum aestivum) has an allohexaploid (AABBDD) 
genome around 17Gb in size (Brenchley et al. 2012; The International 
Wheat Genome Sequencing Consortium 2014). This is likely too large 
for subsequent WGS studies at the current price of sequencing and data 
storage. Wheat is an extremely important crop for both human and 
livestock consumption and genetic improvement is slow; with the 
human population increasing and additional challenges from environ-
mental changes it is essential to gain a better understanding of the crop 
in order to improve it. An exome capture kit has been designed for 
wheat based on the accumulated transcriptome data (Winfield et al. 
2012). The capture region for this kit is 56.5Mb, which is around the 
lower estimated size of one diploid wheat exome, and owing to similar-
ity between the three genomes may be sufficient to capture most of the 
exome data from the whole allohexaploid genome. This kit has been 
used to identify induced mutations in the genome to aid studies inves-
tigating gene function, a use that was also applied to the rice (Oryza 
sativa) exome in the same study (Henry et al. 2014) and the soybean 
(Glycine max) exome in a separate study (Bolon et al. 2011). WES in 
soybean has also been used to identify unwanted intracultivar genetic 
heterogeneity in the exome that may affect the plant’s phenotype (Haun 
et al. 2011).
The genome of barley (Hordeum vulgare L.) has not been fully 
sequenced. Barley’s genome is smaller than wheat’s at around 5Gb, but 
is still larger than is practical for routine whole genome sequence analy-
sis and contains repetitive elements that complicate the genome’s 
assembly. A gene space assembly has been produced (The International 
Barley Genome Sequencing Consortium 2012) and a barley exome 
capture kit has been developed based on this assembly (Mascher et al. 
2013). The kit has since been used to identify a mutation involved in 
early maturation, a trait relevant to production (Pankin et al. 2014). 
Exome capture in barley has also been used to identify a gene caus-
ative of many-noded dwarfism (mnd) using mapping-by-sequencing 
(Mascher et al. 2014). The mnd phenotype is a shorter plant with more, 
narrower leaves than the wild type. The mutant in this study was created 
using X-ray mutagenesis; a technique which often causes large dele-
tions. An F2 population between mutant and wild type phenotypes was 
created and 18 mutant individuals and 30 wild type individuals were 
exome sequenced. From these sequences SNPs were identified and al-
lele frequencies of these were used to identify an allele over represented 
in the mutant group. Researchers queried the sequencing reads for 
exome targets that were present in the wild type but not the mutant. 
This lead to the identification of a candidate gene (MLOC_64838.2, 
now HvMND), which has a homolog known to play a role in a similar 
phenotype in rice. Screening of other mutants showing this phenotype 
found a variety of null mutations in this gene. The family to which this 
gene belongs is known to have effects on important production traits 
and may include good selection targets to improve production. 
Identification of new genetic markers
Robert et al. (2014) have designed exome capture probes for the pig, 
used these to sequence the exomes of 96 healthy pigs and identified 
potentially deleterious variants. Bioinformatic analysis identified 
236,608 high confidence predicted variants and 28,115 predicted indels 
in the target region. This work revealed notable gaps in the current 
Ensembl S.scrofa genome annotation and identified a large number of 
potential protein truncating variants. As the pigs tested were healthy, it 
is possible that some of these protein truncating variants have pheno-
typic effects on traits other than those relating to the health of the pigs 
or to the production traits currently under selection. This work is an 
important step in identifying phenotype altering variants in the pig: 
a production animal and medical model.
The barley exome kit has been used to differentiate between markers 
of H. vulgare L. and H. bulbosum L.; H. bulbosum L. is a wild species that 
has superior pathogen resistance and tolerance compared to the 
domestic species and the two can be crossed to improve the domesti-
cated crop, however negative linkage drag on production traits has 
hampered its use in elite barley lines. Using exome sequencing to iden-
tify specific markers can allow selective crossing to be used to incorpo-
rate the beneficial variants without incorporating linked variants that 
are detrimental to production (Wendler et al. 2014). Similarly, the 
wheat exome kit has allowed for discovery of previously unidentified 
markers in the genome which can be used in future genetic studies and 
marker assisted selection (Allen et al. 2013).
Black cottonwood (Populus trichocarpa) has had an exome capture 
kit designed (Zhou and Holliday 2012). P. trichocarpa is a model organ-
ism and was the first tree to have its whole genome sequenced (Tuskan 
et al. 2006). The tree is used in lumber production and in cosmetics. The 
tree has experienced a whole genome duplication fairly recently and the 
exome study found that this does not appear to have had an effect on 
SNP detection through exome sequencing (Zhou and Holliday 2012). 
There is potential to use the identified markers to improve production 
in this species.
Health traits
As with exome sequencing in humans, exome sequencing has been used 
in other mammals to discover variants associated with health traits. 
WES has been used in conjunction with a genome wide association 
study to identify a frameshift mutation causing blindness in Phalène 
dogs (Ahonen et al. 2013). In cattle (Bos taurus), WES has been used 
successfully to identify strong candidate variants for haplotypes relating 
to reduced fertility rates in Holsteins which can be used to selectively 
breed against these detrimental haplotypes (McClure et al. 2014). 
Special considerations for non-human species
For many species, the reference genome is not completed to the same 
standard as the human genome; many species have only a draft genome 
or, as discussed for barley, no reference genome. This is an important 
consideration when using WES in non-human species. Poor annota-
tion of genomes mean that in the design of capture probes, causative 
genes may be missed because they are not annotated whereas with 
whole genome sequencing, the data will be there whether the gene is 
annotated or not. Where available, including predicted genes identified 
from RNA-sequencing data may be beneficial to maximize coverage of 
functional elements in poorly annotated genomes. For example, Robert 
et al. (2014) added an additional 14Mb of data to the capture region in 
pigs using EST evidence. Additionally, errors in the reference genome 
will greatly increase the number of false-positive variant calls in these 
species. This increases computational burden and forces more stringent 
filtering which may inadvertently discard causative variants.
WES may be especially useful for model organisms, particularly 
where the sequences of large numbers of individuals are needed. The 
expense of WGS on large cohorts makes it less feasible in animal studies 
than human studies, particularly in species with fairly large genomes 
such as mice (~3.5Gb) and zeberafish (~1.5Gb), both common model 
organisms. Sequencing a smaller portion of the genome, particularly if 
candidate regions are known and can be targeted, would be more cost-
effective, allow deeper coverage and potentially increase the number of 
individuals that can be used in these studies.
The genomes of animals have different levels of linkage disequilib-
rium (LD), which are often high in domestic species and model organ-
isms with limited effective population sizes. The level of LD may also 
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vary by breed, as demonstrated in the domestic dog (Stern et al. 2013). 
When using exome sequencing to identify causal variants, high LD may 
lead to the identification of a benign variant that is in LD with the caus-
ative variant. In this case, the causative variant may have been missed in 
variant calling or lie outside the sequence space; it is therefore impor-
tant to consider the known function of the element the candidate vari-
ant is associated with and the predicted effect of the variant on function. 
Additionally, efforts to sample individuals that are as outbred as possi-
ble may help to reduce this problem. Another consideration with high 
LD is that it may be possible to use this information in imputation, as 
has been done with other technologies such as imputing genotypes 
from SNP arrays (Hickey et al. 2012), from WGS data (Deelen et al. 
2014; Gudbjartsson et al. 2015) and from human exome data (Auer et 
al. 2012). The larger haplotypes associated with high LD increase the 
accuracy and reduce the computational burden associated with imputa-
tion. Imputation may be less accurate than sequencing; however it 
allows for a larger numbers of individuals to be used at lower coverage 
and may help to reduce problems associated with variable coverage in 
exome sequencing.
EXOME CAPTURE TRANSFERABILITY BETWEEN SPECIES
 The Neanderthal exome was successfully sequenced by Burbano et al. 
(2010) using an exome capture kit designed for the human exome. The 
study compared the Neanderthal exome to human exomes and found 88 
fixed substitutions in 83 genes in the human exomes; these substitutions 
did not appear to be a result of positive selection and may be a result 
of accelerated genetic drift from reduced effective population size in 
humans following historical bottlenecks or reduced purifying selection. 
The kit designed for cattle can also be applied to other bovid species; 
Cosart et al. (2011) demonstrated that the kit could be successfully used 
to capture the exomes of, and identify SNPs in, zebu (Bos indicus) and 
American Bison (Bison bison). This transferability of exome capture 
kits, as also demonstrated in studies involving the sequencing of Nean-
derthals and non-human primates using human capture kits (Burbano 
et al. 2010; Vallender 2011), is possible because despite millions of years 
of divergence, functional elements tend to be highly conserved.
WHY NOT USE GENOME SEQUENCING?
With the price of sequencing falling as rapidly as it has done over the 
past decade, questions have been raised concerning WES’s usefulness in 
the era of affordable WGS. However, WGS is still more expensive than 
WES. The costs of WES consist of the cost of the capture plus the cost 
of sequencing, whereas WGS consists only of the sequencing costs. If 
we assume that the cost of capture remains fixed, then as the costs 
of sequencing fall, the cost of WGS will approach the cost of WES. 
However, at present that is not the case; and it would be unwise to 
assume that the cost of sequence capture will not reduce. 
Human genomes are a special case, in that the HiSeq X platform 
offers a cost-per-Gb far less than other platforms, yet is limited (contrac-
tually, rather than technically) to 30X WGS human genomes (Watson 
2014). However, even given that advantage, the $1000 price tag for a 30X 
human genome is (in our estimate) two- to three- times the cost of a 40X 
human exome (depending on scale). It may be advantageous to sequence 
more samples using WES, and gain statistical power, than to sequence 
more of the genome. In other species, the price difference is even higher 
– for example, in pigs (a similar sized genome to human but currently 
without the benefit of access to the HiSeq X platform) we estimate the 
cost of WGS to be 9-10 times the cost of WES (Robert et al. 2014).
While WGS does have benefits over WES, the cost of this technolo-
gy is more than simply the price of sequencing. While sequencing tech-
nology has been improving at a much faster rate than would be pre-
dicted by Moore’s law (a prediction of improvement in computing 
hardware, but often also applied to other technologies), the technology 
for storing and analysing the data has not seen a matching acceleration 
in improvement (Mardis 2010; Sboner et al. 2011). WGS produces 
around one hundred times the data that WES does at the same cover-
age. The infrastructure needed to store, manage and analyse data sig-
nificantly increases the costs of WGS. WGS produces a much larger 
number of variants than WES does, not only because of the size of the 
sequencing space, but because regions outside the exome are less well 
conserved; while this number might include a variant of interest, the 
larger data set significantly increases the computational burden for 
analysis. Additionally variation in non-coding regions is less well 
understood than variation in the coding region (Mu et al. 2011; Mau-
rano et al. 2012; Ward and Kellis 2012), making it more difficult to pre-
dict which variants might be relevant to a trait of interest in WGS data-
sets. The majority of causative variants identified so far in Mendelian 
disease have been found in coding regions (Botstein and Risch 2003), 
although ascertainment bias is likely to play a role in this conclusion. A 
study investigating functional non-coding variants based on WGS data 
from 1092 human genomes showed that functionally deleterious non-
coding mutations were under strong negative selection, in a similar way 
to that of loss-of-function variants in protein-coding regions (Khurana 
et al. 2013). The authors developed a tool to prioritize non-coding vari-
ants in disease studies, which was used to identify non-coding candi-
date drivers in tumour genomes.
With the continuous decrease in sequencing cost, new studies mak-
ing use of WGS to investigate causative variants will lead to the discov-
ery of additional mutations in regulatory elements that contribute to 
the pool of disease-associated variants. In that context, the sampling 
bias currently observed towards coding variants is likely to be reduced 
by WGS investigations of non-coding genomic regions.
However, cost is not the only consideration. WGS covers the whole 
genome at more consistent coverage than WES, can provide more 
accurate detection of structural variants and does not have reference 
sequence bias caused by probe sequences in WES (Majewski et al. 2011; 
Meynert et al. 2014; Belkadi et al. 2015). Recent studies have highlighted 
and suggested roles for promoters (The Fantom Consortium et al. 2014) 
and enhancers (Andersson et al. 2014) in a range of different cell types, 
and these are not traditionally captured by exome sequencing. Impor-
tantly, WES requires prior knowledge of the location and sequence of 
features in order to target them, whereas WGS covers the entire ge-
nome. This means that exome sequencing relies on the accuracy of the 
genome annotation, so phenotype altering variants may be missed in 
poorly or incompletely annotated genomes. It is therefore important to 
take care when designing the capture region or purchasing a commer-
cial kit to ensure any specific regions of interest are included. Exome 
sequencing also invariably fails to successfully capture the entire target 
region (Asan et al. 2011; Bodi et al. 2013; Chilamakuri et al. 2014; Rob-
ert et al. 2014), causing even properly annotated regions to be missed. 
Another consideration is that exome sequencing involves a PCR stage 
which is known to reduce coverage of GC-rich regions (Kozarewa et al. 
2009; Veal et al. 2012). New sequencing technology has allowed for se-
quencing of DNA without the need for DNA amplification, generating 
sequencing from single molecules. This technology can produce accu-
rate, longer reads without the artefacts and biases associated with the 
amplification process in other sequencing methods and the exome cap-
ture stage of WES (Shin et al. 2013). The longer read length in these 
third-generation sequencers is particularly beneficial for detecting 
structural variants and for resolving repetition in assemblies and copy 
number variable regions (Roberts et al. 2013). However, for now the 
price of this long-read sequencing is still prohibitively expensive and is 
not commonly in use for analysis of genetic variation. In the future as 
these sequencers improve and prices come down they may make WGS 
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more attractive to researchers even if their analysis focusses solely on 
the protein-coding region and known functional elements. 
The power of WGS on a large cohort for variant discovery has 
already been demonstrated by Gudbjartsson et al. (2015), who se-
quenced the whole genomes of 2,636 Icelanders to 20X and imputed the 
sequence variants into 101,584 further chip-genotyped and phased 
individuals from the same population. This allowed for discovery of 
6,795 null mutations in 4,924 genes which may play a role in disease. 
They also found evidence of lethal mutations that are not found in the 
homozygous state, which likely impact on fertility in heterozygous cou-
ples. Imputation reduces the amount of sequencing and data storage 
required, though the study found that fewer null mutations were 
detected in the imputed data set suggesting that some mutations were 
missed in these individuals.
WGS will eventually take a leading role in genome interrogation; 
however, it will likely have to wait for data storage and analysis to 
improve before its full potential can be realised. In the meantime, WES 
provides many of the benefits of WGS with lower storage requirements 
and computational burden, at an affordable price. This is particularly 
useful in large scale studies, for example, a recent study sequenced the 
exomes of over 9,000 people (Schick et al. 2015). It is also useful for the 
sharing of information such as in the ExAC database where there are 
over 60,000 exomes stored. WES will likely also remain the method of 
choice in species with exceptionally large genomes, for example in some 
polyploid plant species.
CONCLUSIONS
Exome sequencing is a technology that allows interrogation of the most 
well understood portion of the genome: the protein-coding sequence 
and functional elements. Variants of interest don’t necessarily fall with-
in the exome, but so far most of the known variants responsible for 
Mendelian disease have been found in the coding region and the target 
region can be extended to include other regions of interest. While the 
falling price of sequencing may soon make genome sequencing more 
attractive, the additional costs of data handling and downstream analy-
sis cannot be ignored. The applications of variant discovery, particu-
larly in disease gene identification, cannot afford to wait for data storage 
and processing technology to catch up to sequencing improvements. 
The amount of data produced by WES is far more manageable than 
WGS; particularly for small research groups and groups studying 
organisms with large genomes. WES has established itself as an impor-
tant method in disease gene identification in humans, and increasingly 
in domestic species. The applications of WES in crop research is allow-
ing genomic techniques to be used in species with complex genomes, 
potentially identifying variants important for production that can be 
incorporated into marker-assisted selection. At present, WES is a useful 
and powerful method for variant discovery within coding regions offer-
ing most of the benefits of WGS while allowing for easier analysis and 
storage of the data produced.
However WGS will eventually be the NGS technology of choice with 
regard to the investigation of genomic variations due to the more uni-
form coverage achieved with WGS-versus WES- including coverage 
within the exome (Belkadi et al. 2015) and the more uniform distribu-
tion of sequencing quality parameters (e.g. coverage depth, genotype 
quality) observed with WGS- versus WES-(Meynert et al. 2014; Belkadi 
et al. 2015). Additionally WGS extends the variation search space to the 
whole genome allowing for the additional detection of non-coding vari-
ants (The 1000 Genomes Project Consortium 2012), the functional 
impact of which is becoming easier to interpret with the systematic 
annotation of functional non-coding elements (The ENCODE Project 
Consortium 2012; Ward and Kellis 2012; Andersson et al. 2014; The 
Fantom Consortium et al. 2014).
Ideally -regardless of sequencing costs and storage limitations-, 
integrated approaches combining the advantages of both WES and 
WGS would be beneficial for variant discovery studies with the addition 
of WES-/WGS-exclusive variants with WES providing additional vari-
ants missed in low-coverage dataset (The 1000 Genomes Project Con-
sortium 2012). Additionally, both technologies’ usefulness depend 
on the quality of the reference assembly that the sequenced reads are 
mapped to; poor quality references increase the number of false- 
positive variants identified in the analysis, which inevitably leads to 
more stringent filtering, increasing the potential for discarding a variant 
of interest. In the future, the improvement of reference assemblies, 
bioinformatic tools and sequencing technology will be necessary to 
improve the power of variant discovery techniques. 
The term “exome” may no longer be appropriate for a technique 
which is simply a subset of the more generic technique of sequence 
capture. It is already possible to extend the exome capture region 
beyond protein coding genes to capture non-coding genes, and regu-
latory elements such as promoters and enhancers. In this way, we may 
sequence all of the functional areas of a genome without the cost of 
sequencing everything. Indeed, as clinically important variants are 
discovered, the paradigm may change to sequencing small panels 
of genes that are known to be relevant to disease, as is common in 
cancer genomics.
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